about
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetesEstimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study.Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.Intrapulmonary administration of insulin to healthy volunteers.Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus.Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes.Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study.Accuracy and reliability of continuous glucose monitoring in individuals with type 1 diabetes during recreational diving.Combined effects of brachial pulse pressure and sialic acid for risk of cardiovascular events during 40 years of follow-up in 37,843 individuals.The impact of smoking on inhaled insulin.Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.Glucose changes and working memory in individuals with type 1 diabetes during air pressure changes simulating skydiving.Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.Evaluation of glucose control when a new strategy of increased carbohydrate supply is implemented during prolonged physical exercise in type 1 diabetes.Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.Continuous glucose monitoring--a study of the Enlite sensor during hypo- and hyperbaric conditions.Swedish recommendations on recreational diving and diabetes mellitus.Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetesPeriodontal conditions in 70-year-old women with osteoporosis[Clinical experiences with Levemir treatment]Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting[Diving in diabetes possible but not without risks]Late-onset familial neurohypophyseal diabetes insipidus due to a novel mutation in the AVP geneResource utilisation and costs for the treatment of diabetes in the developed world: an economical burden that needs to be solvedWillingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results[Measuring blood ketones--when, where and how]Sialic acid and incidence of hospitalization for diabetes and its complications during 40-years of follow-up in a large cohort: the Värmland surveyImproved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trialsThe Use of eHealth for the Care of Patients With Diabetes in Connection to the COVID-19 PandemicHealth-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes
P50
Q31082841-2CD7034E-BA16-47E5-B25C-AD2DEADADE60Q34583341-A6111F1E-0BF3-4368-BEE8-63E7ECEE93A3Q36097341-A50CC6AB-B334-4A77-8222-8DDC49E594CEQ36489848-69719F4A-3AD8-45BA-B103-7143ACCC500DQ36629179-B88B062F-D30E-4FA8-90F1-93EDABD1FCC1Q38026582-D93F0670-E6A1-4E33-AECF-E864353A1883Q40932296-76C7A788-4938-4BF9-9A77-F1399CD79F9AQ43066575-EF4EF5B1-1BE5-4F2D-8C51-F9C333973011Q43159245-F60CA78C-A265-4AEE-957D-51184BBA8EECQ43162994-DDED3D39-1F7B-4FFC-8D7E-7D0C73B93B0EQ43288109-1C896E2A-77A5-467D-9F95-8F013DBA37A9Q43997599-73743C0E-B1CB-4C40-A7C0-5C7513BC86F5Q44333456-95E7A3C7-E0D3-4143-B86A-04CA4C4E8BB5Q44455232-82F59463-9C03-47CA-B138-E6122B0D1CB6Q44777895-6884F3DB-3C2E-49A4-AD63-2D3BC2A6CC5DQ47348612-8D4ACF24-2179-4880-8EDF-8CAEE5FC7991Q48137451-96A0B68E-6F3E-47B2-8D38-B2B6BA457053Q48264152-543B048B-BD0B-4D96-B009-5254C628793DQ50554731-B07D71F2-4B08-4591-BF3A-0AE4BB9A6190Q51399576-D80D4BFE-5C1F-4740-9D58-AFF0321CADAFQ53118863-C696D5E5-88C9-4BF1-9C81-E5E8943EB117Q53837007-E25B3D86-9013-4B1D-A0F6-97E4AF7134ECQ57413008-CD69649E-D619-4F8D-A2AF-796480D4058AQ77552338-3252D30E-19BE-4992-9E3F-67115121E7A2Q79834126-CFFA05A3-93AB-4E57-A703-8DF25E6C7F4CQ81274707-9621115C-B78C-4729-9D03-D69D71B06F66Q82931559-F196B649-AF2C-4BB3-BA53-F34A4E78BF85Q83958077-865CA1E7-2841-47F2-8121-357A1ADBCB0EQ84152813-2DDF1ED4-D5A0-46B0-A2E5-DC8E3960D82DQ84701376-3A1847DE-666D-4C8E-91FD-087EB102BB7EQ85652692-2C650A8F-35D9-4817-BB15-47DF25DAE27DQ88221303-691A7C1C-ED77-4EFB-B097-6C4787C84263Q92873318-93D0F63D-CB81-4D56-A8E5-7260E93946D4Q94583869-54CB633D-E351-4146-ADD2-BC961CD1E3FFQ95614606-A834E2B7-C32D-4DE7-B4AA-F0670BCD623C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
J Jendle
@ast
J Jendle
@en
J Jendle
@es
J Jendle
@nl
type
label
J Jendle
@ast
J Jendle
@en
J Jendle
@es
J Jendle
@nl
prefLabel
J Jendle
@ast
J Jendle
@en
J Jendle
@es
J Jendle
@nl
P106
P1153
6603020949
P31
P496
0000-0003-1025-1682